SBF
DFTX

Sara-Bay Financial’s Definium Therapeutics DFTX Stock Holding History

Sara-Bay Financial’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,080
Closed -$38K – 84
2021
Q3 		$38K Sell
1,080
-200
-16% -$8.65K 0.01% 76
2021
Q2 		$66K Buy
+1,280
New +$67.2K 0.02% 78

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BB
Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Sara-Bay Financial's DFTX Position: Q4 2021 in Review

Sara-Bay Financial sold out of Definium Therapeutics (DFTX) in Q4 2021, closing a stake of 1,080 shares — an estimated $38K sold.

Sara-Bay Financial first reported a position in DFTX in Q2 2021 and held it in 2 quarters. The position peaked at $66K in Q2 2021. 176 funds tracked by Wall St. Rank hold DFTX as of Q4 2021.

  • Sara-Bay Financial reported no remaining Definium Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Sara-Bay Financial sold 1,080 Definium Therapeutics shares in Q4 2021, an estimated $38K.
  • Sara-Bay Financial first reported a position in Definium Therapeutics in Q2 2021 and held it in 2 quarters.
  • Sara-Bay Financial's Definium Therapeutics position peaked at $66K in Q2 2021.
  • 176 funds tracked by Wall St. Rank held Definium Therapeutics as of Q4 2021.

Based on Sara-Bay Financial's 13F filing for Q4 2021, filed 14 Jan 2022.